CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients
This study demonstrated that polymorphism at rs1057910 significantly affected therapeutic response of gliclazide in type 2 diabetes mellitus patients. It associated with the decrease of FPG and the rate of treatment success in the gliclazide monotherapy.
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
John Wiley and Sons Inc.
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009140/ |